This review frames BPC-157 as a mediator of both stomach cytoprotection and a broader stress-coping response that protects multiple organ systems.
6+ organ systemsNumber of organ systems where BPC-157 demonstrates protective effects in preclinical studies
What the researchers found
BPC-157 demonstrates protective effects across multiple organ systems beyond the stomach, including endothelial protection, vessel recruitment around occlusions, and counteraction of cancer cachexia through modulation of FoxO3a, p-AKT, p-mTOR, and p-GSK-3β pathways.
Why it matters
By connecting BPC-157 to established physiological concepts like Robert's cytoprotection and Selye's stress response, this review provides a theoretical framework for understanding how a single gastric peptide might exert such wide-ranging protective effects.
The numbers in context
Multiple organ systems protected; modulates FoxO3a, p-AKT, p-mTOR, p-GSK-3β in muscle; counters IL-6 and TNF-α
How the study worked
Narrative review synthesizing published preclinical evidence on BPC-157 across cytoprotection, organoprotection, vascular effects, and anti-cachexia mechanisms.
Who was studied
Review of animal studies
What this study cannot tell us
As a narrative review, the paper primarily synthesizes preclinical animal data. Most of the cited evidence comes from a single research group. Human clinical trials are largely absent, and the breadth of claimed effects warrants cautious interpretation.
How to read the evidence
Rated preliminary because while the review covers extensive preclinical data, the evidence is predominantly from animal models and largely from a single research group, with limited independent replication.
When this study was published
Published in 2020, this review synthesizes decades of BPC-157 research and remains a relevant overview of the peptide's proposed mechanisms.
The bigger picture
If BPC-157 truly mediates the body's innate cytoprotective and stress-coping mechanisms, it could represent a fundamentally new therapeutic approach — working with the body's existing defense systems rather than targeting individual disease pathways.
Questions still open
- Can the cytoprotective mechanisms demonstrated in animals be reliably reproduced in human clinical trials?
- What is the optimal route and dosage for achieving organ-specific protection in humans?
- How does BPC-157 interact with conventional therapies for conditions like cancer cachexia or ischemic injury?
Common questions
What is Robert's cytoprotection and how does BPC-157 relate to it?
Does this review provide evidence for BPC-157 use in humans?
Read the original research
Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future.
Gut and liver, 14(2), 153-167
Citation
Sikiric, Predrag; Hahm, Ki-Baik; Blagaic, Alenka Boban; Tvrdeic, Ante; Pavlov, Katarina Horvat; Petrovic, Andrea; Kokot, Antonio; Gojkovic, Slaven; Krezic, Ivan; Drmic, Domagoj; Rucman, Rudolf; Seiwerth, Sven. (2020). Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future.. Gut and liver, 14(2), 153-167. https://doi.org/10.5009/gnl18490